LOGIN  |  REGISTER
C4 Therapeutics
Compass Therapeutics

Syra Health Receives a Contract Extension from Indiana Veterans' Home

January 25, 2024 | Last Trade: US$0.40 0.02 5.99

CARMEL, Ind., Jan. 25, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company addressing some of healthcare's most significant challenges by providing innovative services and technology solutions, announced today that it has received a contract extension from the Indiana Veterans' Home to continue to provide its healthcare workforce solutions.

The extension brings the total contract amount to $264,000. Under the extension, Syra Health provides on-demand temporary medical personnel through the end of fiscal year 2024.

"This contract extension demonstrates the value we bring to our partners," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "Syra Health has a large healthcare talent pool to supplement the ongoing healthcare workforce shortage."

The Indiana Veterans' Home provides long-term skilled care to veterans. Its mission is to honor Indiana's veterans and their spouses by providing the highest level of care in a therapeutic home-like environment, enhancing health, and yielding optimal quality of life.

ABOUT SYRA HEALTH CORP. 

Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental healthdigital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. For more information, please visit www.syrahealth.com.

FORWARD-LOOKING STATEMENTS

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.

For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it. 

C4 Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB